Beta Bionics, Inc. (NASDAQ:BBNX) Receives $26.42 Consensus Price Target from Brokerages

Beta Bionics, Inc. (NASDAQ:BBNX) has been given an average recommendation of “Moderate Buy” by the thirteen brokerages that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation, six have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $26.4167.

Several equities analysts have recently issued reports on the stock. Truist Financial cut their price objective on shares of Beta Bionics from $37.00 to $25.00 and set a “buy” rating on the stock in a report on Monday, February 2nd. Stifel Nicolaus decreased their target price on Beta Bionics from $31.00 to $25.00 and set a “buy” rating for the company in a research report on Wednesday, February 4th. Piper Sandler restated an “overweight” rating and set a $32.00 target price (up from $26.00) on shares of Beta Bionics in a research report on Wednesday, October 29th. Robert W. Baird set a $28.00 price objective on shares of Beta Bionics in a report on Tuesday, December 16th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and issued a $25.00 price target on shares of Beta Bionics in a report on Thursday, January 15th.

Beta Bionics Stock Performance

NASDAQ BBNX opened at $14.12 on Monday. The business’s 50 day moving average price is $23.32 and its 200-day moving average price is $22.60. The company has a market cap of $621.70 million and a P/E ratio of -3.23. Beta Bionics has a fifty-two week low of $8.89 and a fifty-two week high of $32.71.

Insider Buying and Selling at Beta Bionics

In other news, CFO Stephen Feider sold 20,000 shares of the company’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $29.53, for a total transaction of $590,600.00. Following the completion of the sale, the chief financial officer owned 42,614 shares in the company, valued at approximately $1,258,391.42. This represents a 31.94% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Mike Mensinger sold 7,800 shares of the business’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $29.61, for a total value of $230,958.00. Following the transaction, the insider owned 82,952 shares in the company, valued at $2,456,208.72. This represents a 8.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 32,490 shares of company stock worth $960,835 over the last three months.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in BBNX. Vanguard Group Inc. raised its position in Beta Bionics by 213.5% in the 3rd quarter. Vanguard Group Inc. now owns 2,216,185 shares of the company’s stock valued at $44,036,000 after buying an additional 1,509,217 shares during the last quarter. Divisadero Street Capital Management LP bought a new stake in shares of Beta Bionics in the second quarter valued at approximately $13,817,000. Sands Capital Alternatives LLC lifted its position in shares of Beta Bionics by 15.0% during the second quarter. Sands Capital Alternatives LLC now owns 3,570,113 shares of the company’s stock worth $51,981,000 after acquiring an additional 466,331 shares in the last quarter. Soleus Capital Management L.P. lifted its holdings in Beta Bionics by 12.5% during the 2nd quarter. Soleus Capital Management L.P. now owns 3,820,158 shares of the company’s stock worth $55,622,000 after purchasing an additional 424,817 shares in the last quarter. Finally, Norges Bank bought a new position in shares of Beta Bionics in the fourth quarter valued at approximately $10,338,000.

About Beta Bionics

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.